Feb 10, 02:31 PM

Eli Lilly Collaborates with Advancell on Cancer Therapies, $2.5 Billion Acquisition of Scorpion Drug, Files for Notes Offering

Eli Lilly has entered into a strategic collaboration with Advancell to advance novel targeted alpha therapies aimed at cancer treatment. In addition, Eli Lilly is preparing to tap the U.S. investment-grade bond market to finance its approximately $2.5 billion acquisition of a cancer drug from Scorpion Therapeutics. The company is also seeking to expand its operations into cancer radiopharmaceuticals and fatty liver disease through two global deals. Furthermore, Eli Lilly has filed for a six-part notes offering, although the size of this offering has not been disclosed.

#Eli Lilly #Advancell #Scorpion Therapeutics

Written with ChatGPT (GPT-4o mini).

Sources

LeguideBoursier.com@leguideboursier
2 years ago
AdvanCell noue une collaboration stratégique avec Lilly pour développer les nouvelles alphathérapies ciblées pour le traitement du cancer https://t.co/mBNXJIhn9q
BioCentury@BioCentury
2 years ago
BioCentury's Deals Report: Immunology in-licensing company Acelyrin merges with Alumis after its lead program fizzled; plus, Advancell tightens ties with Lilly, and more https://t.co/mMLX7vUZPY
CHItrader@CHItraders
2 years ago
$LLY Eli Lilly Seeks To Expand Into Cancer Radiopharma And Fatty Liver, With Two Global Deals https://t.co/yGZ2Tu3Thz

Eli Lilly Collaborates with Advancell on Cancer Therapies, $2.5 Billion Acquisition of Scorpion Drug, Files for Notes Offering

Sources

Additional media

Similar Stories